Development research on immuno-gene therapy for malignant B-cell lymphoma

针对难治性恶性B细胞淋巴瘤（B-cell non-Hodgkin lymphoma，B-cell non-Hodgkin lymphoma）的治疗，我们进行了使用表达针对CD 19的嵌合抗原受体（chimeric antigen receptor，CAR）的T细胞的过继免疫基因治疗的实验。这些结果表明，功能性工程化T细胞将有效治疗难治性B细胞非霍奇金淋巴瘤。

For the treatment of refractory malignant B-cell lymphoma(B-cell non-Hodgkin lymphoma), we conducted experiments to develop an adoptive immuno-gene therapy using T-cells expressing a CAR(chimeric antigen receptor) targeting CD19.We demonstrated that genetically engineered T-cells efficiently lyzed CD19-positive B-cell lymphoma in vitro and in a mouse xenograft model. These results indicate that functional engineered T-cells would be effective for the treatment of refractory B-cell non-Hodgkin lymphoma.